MAPT and Alzheimer disease: In animal models representing PD and AD, SkQ1 has shown promising results such as reduction in excessive phosphorylation of Aβ and tau proteins, improvement in memory and learning abilities, as well as the delay of mitochondrial dysfunction and neurodegenerative changes [262–264].